Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
59.20
+2.31 (4.06%)
At close: Jun 26, 2026, 4:00 PM EDT
60.02
+0.82 (1.39%)
After-hours: Jun 26, 2026, 6:46 PM EDT
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
| Name | Position |
|---|---|
| Dr. John F. Paolini FACC, M.D., Ph.D. | Executive VP & Chief Medical Officer |
| Mr. Aaron Young | Chief Intellectual Property Officer |
| Mr. Eben Tessari | Consultant |
| Mr. Jonathan Kirshenbaum | Investor Relations Officer |
| Mr. Joseph Pirrello | Chief Business Officer |
| Mr. Mark A. Ragosa C.F.A. | Executive VP & CFO |
| Mr. Michael R. Megna CPA | Senior VP & Chief Accounting Officer |
| Mr. Ross Michael Moat | Executive VP, COO & Principal Operating Officer |
| Ms. Martina Struck Ph.D. | Senior VP & Chief Regulatory Officer |
| Ms. Mei Jang | Senior VP & Chief Technical Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-29 | 8-K | knsa-20260529x8k.htm |
| 2026-05-26 | 8-K | knsa-20260521x8k.htm |
| 2026-05-01 | 8-K | knsa-20260430x8k.htm |
| 2026-04-28 | 8-K | knsa-20260428x8k.htm |
| 2026-04-28 | 10-Q | knsa-20260331x10q.htm |
| 2026-04-16 | DEFA14A | tm261439d5_defa14a.htm |
| 2026-04-16 | DEF 14A | knsa-20260519xdef14a.htm |
| 2026-04-16 | ARS | tm262870d2_ars.pdf |
| 2026-02-24 | S-8 | tm266974d1_s8.htm |
| 2026-02-24 | 8-K | knsa-20260224x8k.htm |